Combination Dosing Regimen Not Obvious Despite Overlapping Prior-Art Ranges Justin J. Gillett & Alex Martin del Campo JANSSEN PHARMACEUTICALS, INC. v. TEVA PHARMACEUTICALS USA, INC. Before Prost, Reyna, and Taranto….
Space Technology Investments Clear the Launch Tower in 2025 Tom Cowan Investments in space technology are off to a strong start in the first half of 2025. The rising trend…
July Federal Circuit Newsletter (Japanese) July Federal Circuit Newsletter (Chinese) Combination Dosing Regimen Not Obvious Despite Overlapping Prior-Art Ranges In Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., Appeal…
June Federal Circuit Newsletter (Japanese) June Federal Circuit Newsletter (Chinese) No Injury, No Appeal: Patent Owners Must Show Actual Injury for Article III Standing In Dolby Laboratories Licensing Corporation…
May Federal Circuit Newsletter (Japanese) May Federal Circuit Newsletter (Chinese) Invoking the Hatch-Waxman Safe Harbor Does Not Necessarily Require Factual Development That Such Activities Fall Within its Scope In…
April Federal Circuit Newsletter (Japanese) April Federal Circuit Newsletter (Chinese) Ready or Not, Here I Come: When Is a Trade Secret Publicly Accessible? In Ams-Osram USA Inc. v. Renesas…
March Federal Circuit Newsletter (Japanese) March Federal Circuit Newsletter (Chinese) Limits of Inherent Anticipation in Product-by-Process Claims In Restem, LLC v. Jadi Cell, LLC, Appeal No. 23-2054, the Federal…
February Federal Circuit Newsletter (Japanese) February Federal Circuit Newsletter (Chinese) Every Word Counts: Specification Naming Conventions Can Limit Claim Scope In HD Silicon Solutions LLC V. Microchip Technology Inc.,…
January Federal Circuit Newsletter (Japanese) January Federal Circuit Newsletter (Chinese) Motivation to Modify Under Obviousness Standard Does Not Need to Align with Patentee’s Goal In Honeywell International Inc. v….
December Federal Circuit Newsletter (Japanese) December Federal Circuit Newsletter (Chinese) Bound to Happen: Inherent Property Leaves No Question of Reasonable Expectation of Success In Cytiva Bioprocess R&D Ab v….
